Close Menu

NEW YORK (GenomeWeb News) – Stemina Biomarker Discovery said this week that it has raised $1 million in angel investments to further develop its product for assessing drug toxicity in the developing human embryo.

Angel groups DaneVest Tech Fund Advisors, Phenomenelle Angels, and Wisconsin Investment Partners all contributed to the financing.

Stemina said that it plans to raise a total of $3 million in the financing round. In addition, the company said that it was recently awarded a $150,000 grant from the National Science Foundation.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.